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http://dx.doi.org/10.1053/j.gastro.2013.07.056Reply. We thank the authors for their interest in our
randomized trial comparing endoscopy and surgery for
pseudocyst drainage. All patients screened for participation
in our study had a computed tomography (CT) scan that was
reviewed by a dedicated expert in body imaging. The study
cited by Talukdar and colleagues where CT could detect ne-
crosis in only 23% of patients was actually conducted at our
institution in Alabama nearly 16 years ago.1 Since then, the
quality of CT imaging has signiﬁcantly improved. In the
most recent study from South Korea that compared CT and
magnetic resonance imaging (MRI), none of the patients
diagnosed with necrosis were missed by either modality
although MRI correlated better with clinical outcomes.2 The
limitation with CT imaging was that it overestimated the
severity grading in almost all cases. The presence of debris
within a ﬂuid collection is estimated (rather incorrectly)
based on Hounsﬁeld units. In our study, more than 40% of
patients were excluded as they had necrosis based on CT
imaging. None of these patients at endoscopic ultrasound
had necrotic debris. It is possible that some patients in the
surgical cohort had liqueﬁed necrosis that was managed by
only cystogastrostomy but none required intraoperative
debridement. The relevance of minimal debris in the clinical
management of pancreatic pseudocysts is unclear.
We agree with the comments that the acuteness or chro-
nicity of pancreatitis is more relevant than that of the ﬂuid
collection itself. Twenty-nine of40 (72%)patients in this study
were recruited from outpatient clinics and others as inpatient
admissions or transfers from outside hospitals. While almost
all outpatient enrollments had documented, long-standing
chronic pancreatitis, with the exception of three cases, we
are unsure about disease chronicity in 8 (20%) other patients.
The objective of the randomized trial was to compare 2
different standards-of-care techniques, surgery vs endos-
copy. None of the patients undergoing surgical cystogas-
trostomy routinely have preoperative endoscopic retrograde
cholangiopancreatography or magnetic resonance chol-
angiopancreatography to assess for ductal integrity and is
not considered standard-of-care. As surgeons do not request
pancreatic duct stent placement prior to cystogastrostomy to
manage duct leak, the need for assessment of ductal integrity
in uncomplicated pancreatic pseudocysts is unclear. We
opine that routine evaluation of the ducts prior to surgery
would be an academic exercise with limited practical utility.
The single patient who failed treatment in the endoscopy
cohort had inadequate drainagewith transmural stenting and
not a persistent pancreatic duct leak as this had resolvedwith
transpapillary stenting.In the United States, most surgical cystogastrostomy
procedures are currently being performed via the open
approach and not laparoscopy. We agree that a laparoscopic
approach has lower morbidity and possibly expedites hos-
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http://dx.doi.org/10.1053/j.gastro.2013.11.031Non-Celiac Wheat Sensitivity Is a
More Appropriate Label Than Non-
Celiac Gluten Sensitivity
Dear Sir:
We have read with great interest the article by Biesie-
kirski et al,1 in which a double-blind, placebo-controlled
(DBPC) rechallenge study demonstrated a lack of evidence
of speciﬁc or dose-dependent effects of gluten in patients
with non-celiac gluten sensitivity (NCGS) while on a low
FODMAP diet. The authors themselves noted that these data
are inconsistent with their previous study,2 and considered
the strict control on the patients’ diet throughout the entire
study a pivotal difference. During the new study, all patients
consumed a diet including foods with low FODMAP content
and this led to an immediate improvement of the irritable
bowel syndrome (IBS) symptoms, irrespective of the
successive gluten challenges.1
Although we agree that FODMAP consumption can play
an important role in determining IBS-like symptoms, we
would like to underline some factors that merit further
consideration and research. First: a major change in dietary
habits modiﬁes the intestinal microbiota and it is well
known that this can be crucial in IBS pathogenesis;3 future
studies should also consider the microbiota, and not only
the FODMAP content, in evaluating the results. Second: in
a previous paper we found that about one-third of IBS pa-
tients improved on elimination diet and worsened on DBPC
January 2014 Correspondence 321challenge with wheat and cow’s milk proteins,4 and
suggested that a percentage of them could suffer from
non-IgE-mediated food allergy. However, the great major-
ity of the patients we studied showed intra-epithelial
inﬂammation in the duodenal mucosa (Marsh 1 lesion), a
criterion considered “of exclusion” in the Biesiekirski’s
study.1 Thus, 2 different patient populations with NCGS
were studied and the results cannot be compared.
However, since mucosal inﬂammation is a characteristic of
intestinal allergic diseases, and Marsh 1 lesion can be
present in several conditions other that celiac disease, we
would suggest not excluding patients with duodenal
lymphocytosis from future studies. Third: it is of interest
that 37% of the patients recruited in the Biesiekirski’s
study had elevated values of serum IgA anti-gliadin anti-
bodies. This value is greater than those reported in IBS
patients, and in the absence of other reliable markers,
supports a possible role of serum anti-gliadin antibodies
assay in suspecting NCGS. Fourth: we were intrigued that
Biesiekirski and colleagues found the highest percentage of
patients reacting to the DBPC challenge in the group of
those who consumed whey proteins as placebo.1 Although
the patient selection greatly differed from ours,4 the
described reaction to the whey proteins is consistent with
the very frequent association between wheat and cow’s
milk sensitivities which we have reported.4 The lack of
reproducibility of the reaction to whey proteins during the
second DBPC challenge, observed by Biesiekirski et al,1
could be due to the short-term administration (3 days) of
the whey proteins. Very delayed reactions to food antigens
have been described, with symptom onset between 7 and
26 days after the beginning of the challenge.5
We thank Biesiekirski and collegues for their important
study and hope they agree that not-celiac wheat sensitivity
(NCWS)4 is now a better label than NCGS and that NCWS
more accurately describes patients with different clinical
presentations and different pathogenesis. Any label can be
used but the puzzle is complex.
ANTONIO CARROCCIO
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http://dx.doi.org/10.1053/j.gastro.2013.08.061Reply. The letter from Carroccio et al1 raises several
important issues and we will address them in sequence.
First, it is likely that the 2-week run-in period during
which FODMAPs were reduced2 may have led to changes in
the microbiota of the intestine, as recently reported after 4
weeks’ exposure to dietary restriction of FODMAPs.3 It is
possible that such changes may be one reason for a loss of
a positive response to gluten. However, it must be
stressed that the role of microbiota in the pathogenesis of
irritable bowel syndrome is speculative. What is good and
what is not, and whether changes are secondary or
primary to intestinal conditions remain to a large extent
unresolved for most intestinal conditions rather than
being established as ‘crucial’. We agree that microbiota
should be one part of the puzzle to be teased out in
studies in which diet is being manipulated.
Secondly, we have difﬁculty with the suggestion that
patients with evidence of immune activation in the duo-
denum should be included in a study of non-celiac gluten
sensitivity (NCGS). Such changes might represent celiac
disease or hypersensitivity reactions to wheat-associated
proteins in some patients. The current deﬁnition of NCGS
encompasses the exclusion of both celiac disease and im-
mune responses to wheat proteins.4 Given the early stages
in our understanding of the NCGS entity, we believe we
should strictly keep to this deﬁnition to ensure ﬁndings
do not overlap with other conditions. We do agree,
however, that a study with similar design to ours should
be directed towards the patients with duodenal
intraepithelial lymphocytosis as this is a different group to
those with normal duodenal pathology.
Thirdly, we also have problems with the proposal that
our data suggest circulating antibodies to whole gliadin
could be a biomarker for patients with NCGS. While they
were detected in one-third of the patients in our study, it is
untenable to use this test as a biomarker for NCGS when
none of the cohort studied demonstrated speciﬁc symp-
tomatic reactions to gluten. In fact the opposite seems more
logical. We trust we have not misconstrued the meaning of
the suggestion made.
Fourthly, as evidenced by our study design, we too were
concerned that we had identiﬁed patients who had reactions
to whey proteins. However, all the positive reactions
occurred within the ﬁrst two days of exposure and very few
were speciﬁc to whey. In the second challenge, it would be
anticipated that reactions to a similar dose of whey would
occur again quickly, especially if immune reactions are the
basis for the symptom induction. It is important also to
point out that the rate of placebo responses is a major dif-
ference between our ﬁndings,2,5 and observations of other
groups6 with those in published reports from Carroccio
et al.7 We ﬁnd placebo responses commonly in contrast to
